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Oncogene-induced replication stress (RS) promotes cancer development but also impedes
tumor growth by activating anti-cancer barriers. To determine how cancer cells adapt to RS,
we have monitored the expression of different components of the ATR-CHK1 pathway in
primary tumor samples. We show that unlike upstream components of the pathway, the
checkpoint mediators Claspin and Timeless are overexpressed in a coordinated manner.
Remarkably, reducing the levels of Claspin and Timeless in HCT116 cells to pretumoral levels
impeded fork progression without affecting checkpoint signaling. These data indicate that
high level of Claspin and Timeless increase RS tolerance by protecting replication forks in
cancer cells. Moreover, we report that primary fibroblasts adapt to oncogene-induced RS by
spontaneously overexpressing Claspin and Timeless, independently of ATR signaling. Alto-
gether, these data indicate that enhanced levels of Claspin and Timeless represent a gain of
function that protects cancer cells from of oncogene-induced RS in a checkpoint-independent
manner.
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Genomic instability is a cancer hallmark that is detected atearly stages of tumorigenesis and is generally consideredas a driving force of cancer development1. A growing
body of evidence indicates that DNA damage arises as a con-
sequence of oncogene-induced replication stress (RS)2–4. RS
refers to a variety of events of endogenous or exogenous origin
that interfere with the progression of DNA replication forks5,6. In
cancer cells, RS is caused by the aberrant activation of oncogenes,
which may either increase conflicts between replication and
transcription or uncouple DNA synthesis from nucleotide
metabolism4,7.
RS activates a surveillance pathway known as the replication
checkpoint8. In this pathway, the ATR kinase is recruited to
stressed forks by the accumulation of replication protein A
(RPA)-coated single-stranded DNA and is activated by TopBP1, a
factor loaded at single-stranded/double-stranded DNA junctions
by the 9-1-1 complex (RAD1, RAD9, and HUS1) and its clamp
loader, RFCRAD178. Once activated, ATR phosphorylates the
effector kinase CHK1 on Ser317 and Ser345 to amplify the
checkpoint signal. This process is mediated by Claspin, Timeless,
and Tipin, which form a complex at replication forks and act as
mediators for CHK1 activation9–11. Once activated, the ATR-
CHK1 pathway acts in many ways to coordinate fork repair
processes, prevent premature entry into mitosis and allow the
completion of DNA replication8.
Oncogene-induced RS is a double-edged sword. Although it
contributes to cancer development by promoting genomic
instability, it slows down cell proliferation and activates antic-
ancer barriers leading to apoptosis or senescence12–15. To pro-
liferate, cancer cells must therefore bypass these barriers, while
avoiding severe replicative defects that are incompatible with cell
survival. It is generally believed that cells adapt to oncogene-
induced RS by modulating the intensity of the ATR-CHK1
checkpoint response16–18. Indeed, ATR and CHK1 haplo-
insufficiencies enhance oncogene-induced tumor formation19,20,
but a more severe depletion of ATR is synthetic lethal with
oncogene overexpression19,21. Along the same line, a mild over-
expression of CHK1 in mouse by addition of an extra-copy of the
CHK1 gene decreases oncogene-induced RS and promotes tumor
growth22. Collectively, these data indicate the ATR-CHK1 path-
way has both protumoral and antitumoral activities depending on
the cellular context16,18. Understanding how cancer cells control
this balance represents therefore a major challenge in cancer
biology.
Owing to their central position in the ATR-CHK1 pathway and
their fork association, Claspin, Timeless, and its partner Tipin are
ideally placed to fine tune the cellular response to oncogene-
induced RS. These factors are upregulated in many different
cancers and their increased expression is associated with bad
prognosis23–29. Overexpression of Claspin is also a marker of
radioresistance in metastasis lung cancer30 and Timeless is a
candidate molecular marker for predicting the response of ER α-
positive postmenopausal breast cancer to Tamoxifen31. However,
the mechanism by which Claspin, Timeless, and Tipin promote
cancer progression is currently unclear.
Besides their role in the ATR-CHK1 pathway11,32, Claspin,
Timeless, and Tipin also play a structural role at replication forks
that is independent of their checkpoint function33–36. Indeed,
these three proteins form a complex at replication forks called the
fork protection complex (FPC), which is conserved from yeast to
vertebrates32. Mrc1, Tof1, and Csm3, the budding yeast homologs
of Claspin, Timeless, and Tipin, interact with DNA polymerase ε
and the CMG helicase on the leading strand synthesis37,38 and are
required for normal fork progression in a checkpoint-
independent manner39,40. In vertebrates, Claspin is a DNA
binding protein that associates with branched structures in a
highly specific and strong manner and interacts with numerous
components of the replication machinery, namely MCM proteins,
DNA polymerases (pol) α, δ, ε, CDC7 kinase, and CDC4532,34.
Timeless and Tipin interact with the replicative helicase com-
ponents MCM2-7 and CDC45, and with replicative polymerases
Pol ε and Pol δ, increasing their processivity in vitro32. Since
replication defect in Timeless-depleted cells is synthetic with ATR
depletion35, Timeless could coordinate enzymatic activities at the
fork, independently of ATR.
Here, we have investigated the mechanism by which cancer
cells adapt to oncogene-induced RS by modulating components
of the ATR-CHK1 pathway. We have analyzed the expression of
key components of this pathway in primary lung, breast, and
colon cancer samples and in a variety of cancer cell lines. We
found that unlike the checkpoint sensors ATR, RAD9, and
RAD17, the downstream components of the ATR pathway
Claspin, Timeless, and CHK1 show a correlated overexpression in
cancer cells. To characterize the protumoral effect of this
increased expression, we have reduced the excess of Claspin and
Timeless in HCT116 cells under conditions that do not prevent
checkpoint signaling. We show that this depletion reduces fork
speed, increases fork stalling and leads to accumulation of γ-
H2AX, in a checkpoint-independent manner. Moreover, primary
fibroblasts escaping oncogene-induced senescence overexpress
Claspin and Timeless. Altogether, these data indicate that cancer
cells adapt to RS by overexpressing Claspin and Timeless, inde-
pendently of ATR signaling.
Results
Components of the ATR pathway are overexpressed in cancers.
The ATR-CHK1 pathway controls tumor progression in a
dosage-dependent manner16, but the mechanism by which tumor
cells modulate this pathway to adapt to oncogene-induced RS is
currently unclear. To address this question, we have analyzed the
expression of the checkpoint sensors RAD17, RAD9, and ATR,
the mediators Claspin and Timeless and the effector CHK1
(Fig. 1a) in 93 primary non–small-cell lung cancers (NSCLC)27,
74 primary colorectal carcinomas41, and 206 primary breast
cancers42. For each gene, mRNA levels were determined by a
quantitative real-time polymerase chain reaction (qRT-PCR) and
were expressed relative to normal adjacent tissue (lung and col-
orectal cancers) or to a pool of healthy tissues (breast cancer).
This analysis revealed that Claspin, Timeless, and CHK1 were
overexpressed in these three cohorts (Fig. 1b; T/N > 1) in a cor-
related manner, with a Spearman coefficient ranging from 0.56 to
0.80 (Fig. 1c). In contrast, the expression of the checkpoint sen-
sors ATR, RAD9, and RAD17 was only modestly increased in
cancer samples relative to normal tissues (Fig. 1b), and did not
correlate with the downstream components of the pathway
(Fig. 1c). A clustered expression of Claspin, Timeless, and CHK1
was also observed when a larger number of DNA damage
response (DDR) genes were analyzed (Supplementary Fig. 1c–h),
supporting the view that the downstream components of the
ATR-CHK1 pathway are co-regulated.
In lung cancer, the expression of Claspin, Timeless, and CHK1
correlated also to some extent with PCNA, but this correlation
was not observed in colon and breast cancers (Fig. 1c). In
addition, PCNA mRNA levels were only moderately increased
(1.4-fold) in lung cancer compared to those of Claspin and CHK1
(4.5- and 4.4-fold, respectively; Fig. 1b), indicating that the
increased expression of Claspin, Timeless, and CHK1 in cancer
cells does not simply reflect increased proliferation. Altogether,
these data indicate that the upstream and downstream compo-
nents of the ATR-CHK1 checkpoint are differentially regulated in
primary cancer cells.
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Fig. 1 Claspin, Timeless, and CHK1 mRNA are overexpressed in primary colorectal, lung, and breast cancers. a Schematic representation of the ATR
pathway showing the six checkpoint factors analyzed in this study. b Relative mRNA levels of ATR, RAD9, RAD17, Claspin, Timeless, CHK1, and PCNA in
93 lung tumors, 74 primary colorectal carcinomas, and 206 breast cancer samples. mRNA levels were determined by quantitative RT-PCR and are
expressed as the ratio of tumor (T) to normal tissues (N). c Nonparametric Spearman correlation analysis of the expression of checkpoint genes and
proliferation marker (PCNA) in lung, colorectal, and breast cancer samples. d High expression of Claspin, Timeless, and CHK1 is associated to bad
prognosis in NSCLC patients. Disease-free survival (DFS) according to gene level expression: Claspin, Timeless, CHK1, RAD17, ATR, and RAD9. Totally, 72
patients were analyzed
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Claspin and Timeless are prognostic biomarkers of NSCLC. To
determine whether the overexpression of the downstream com-
ponents of the ATR-CHK1 pathway could have an impact on
cancer development, we focused on a cohort of low grade (IA, IB,
IIA, and IIB) NSCLCs patients who received no adjuvant treat-
ment and asked whether the expression level of components of
the ATR-CHK1 pathway determined at diagnosis had an impact
on their disease-free survival (DFS) over a 72 months period. For
each of these genes, patients were separated in two groups
depending on the level of the corresponding mRNAs. Remark-
ably, the group of patients with tumors overexpressing Claspin,
Timeless, or CHK1 showed a marked decrease in DFS compared
to low-expression group (Fig. 1d). In contrast, the effect of RAD9,
RAD17, and ATR levels was not significant (Fig. 1d). Together,
these data indicate Claspin, Timeless, and CHK1 are frequently
overexpressed in primary cancers independently of upstream
components of the ATR-CHK1 pathway. In lung cancer, this
increased expression was associated with a reduced DFS, sug-
gesting that it could be used as a prognostic biomarker for early
NSCLC. Antibodies against Claspin and Timeless have been
successfully used on paraffin-embedded tumor samples25,26,
which was confirmed here for Timeless with breast cancer sam-
ples (Supplementary Fig. 1a, b).
Claspin and Timeless are overexpressed in cancer cell lines. To
determine how Claspin, Timeless, and CHK1 could promote
tolerance to RS independently of ATR signaling, we first checked
their protein levels in cancer cell lines and immortalized primary
cells. Immunoblots confirmed that unlike ATR and RAD17, levels
of Claspin, Timeless, and CHK1 were highly increased in trans-
formed cells (U2OS, HeLa, and HCT116) compared to immor-
talized primary fibroblasts (IMR90, BJ), immortalized primary
epithelial cells (RPE-1 and MCF10A) (Fig. 2a, b). Chromatin
fractionation experiments also revealed that the amount of
chromatin-bound Claspin and Timeless was proportionally
increased in HCT116 cells (Supplementary Fig. 2), suggesting that
a large fraction of overexpressed proteins was present on chro-
matin and could therefore play a biological role.
Next, we asked whether protein levels of Claspin, Timeless, and
CHK1 are correlated in cancer cell lines. To this end, we
monitored the relative abundance of 18 checkpoint proteins in
the proteomic landscapes of 50 colorectal cancer cell lines43. This
analysis confirmed that the abundance of Claspin, Timeless, and
CHK1 is highly correlated and that these proteins form a cluster
with BRCA1, TopBP1, and Tipin that is distinct from ATR,
ATRIP, RAD9A, HUS1, and RAD1 (Fig. 2c). This is reminiscent
of the correlation observed at the mRNA level in cancer patients
(Supplementary Fig. 1d, f, h) and supports the view that Claspin,
Timeless, and CHK1 are part of a functional module whose
function is distinct from the ATR signaling pathway.
Excess of Claspin is dispensable for CHK1 activation. CHK1
plays pleiotropic roles in the cell and is essential for viability44–46.
We, therefore, focused subsequent analyses on the function of
Claspin and Timeless, using HCT116 colon cancer cells as an
experimental model. To evaluate the functional significance of the
overexpression of Claspin and Timeless in HCT116 cells, we first
expressed shRNAs against these factors and observed a reduction
in cell proliferation, growth on soft agar (Fig. 3a–c) and colony
formation (Supplementary Fig. 3e) relative to control cells. Since
the best-characterized function of Claspin and Timeless is to
mediate checkpoint activation in S phase9,10, we next monitored
the ability of sh-CLSPN and sh-TIM cells to promote CHK1
phosphorylation in response to nucleotide depletion by hydro-
xyurea (HU). Remarkably, CHK1 was efficiently phosphorylated
on Ser 317 in sh-CLSPN and sh-TIM cells (Fig. 3d) and the
CHK1 target CDC25A was rapidly degraded in a CHK1-
dependent manner in HU-treated sh-CLSPN and sh-TIM cells
(Fig. 3e). Similar results were also obtained with a lower dose of
HU (100 µM; Supplementary Fig. 3a) or after a transient trans-
fection with siRNAs against Claspin, Timeless, or both proteins
(Supplementary Fig. 3b). These data indicate that the residual
levels of Claspin and Timeless in sh-CLSPN and sh-TIM cells are
sufficient for the timely activation of the ATR-CHK1 pathway in
response to RS. Efficient CHK1 activation was also observed in
U2OS and MCF7 cells transfected with siRNAs against Claspin
and Timeless (Supplementary Fig. 3c, d), under conditions that
interfere with the growth of MCF7 cells (Supplementary Fig. 3f).
Altogether, these data indicate that the overexpression of Claspin
and Timeless in cancer cell lines promotes cell growth indepen-
dently of their checkpoint function.
High levels of Claspin and Timeless promote fork progression.
In unchallenged growth conditions, the reduction of Claspin and
Timeless levels induced the formation of γ-H2AX in HCT116
cells (Fig. 4c) and in U2OS and MCF7 cells (Supplementary
Fig. 3c–d), which may reflect the induction of spontaneous RS.
Since H2AX can also be phosphorylated by ATM and DNA-PK
outside of S phase47, ongoing DNA replication was labeled with
EdU to specifically monitor γ-H2AX levels in S-phase cells. Flow
cytometry analyses revealed that 60% and 69% of EdU-positive
cells were enriched in γ-H2AX upon reduction of Claspin or
Timeless levels, respectively, whereas it is only the case in 22% of
untreated HCT116 cells (Supplementary Fig. 4a). Immuno-
fluorescence experiments confirmed that γ-H2AX levels in EdU-
positive cells were also significantly higher in sh-CLSPN and
sh-TIM cells relative to control cells (Fig. 4a, b). These data
indicate that the shRNA-mediated reduction Claspin and Time-
less levels in HCT116 cells increases spontaneous RS.
Next, we used DNA combing to monitor the impact of Claspin
and Timeless levels on the progression of individual replication
forks. To this end, sh-Ctrl, sh-CLSPN, and sh-TIM HCT116 cells
were labeled for 10 min with IdU and for 20 min with CldU.
DNA fibers were stretched on silanized coverslips and the length
of CldU tracks was measured as described previously48. CldU
tracks were significantly shorter in sh-CLSPN and sh-TIM cells
than in sh-Ctrl cells (16.6 and 18.4 kb, respectively, vs. 22.1 kb in
control cells, p < 0.001), indicating that replication forks are ~25%
slower upon reduction of Claspin or Timeless levels (Fig. 4d).
This slow fork progression was also confirmed with a related
DNA fiber assay called DNA fiber spreading49, using inducible
shRNAs (Supplementary Fig. 4b) or siRNAs (Supplementary
Fig. 4c) against Claspin and Timeless or both (Supplementary
Fig. 4c). To determine whether this slow fork phenotype is due to
an increased rate of fork stalling, we measured the level of
asymmetry between the distance covered by sister replication
forks, as described earlier50. This analysis revealed a significant
increase in fork asymmetry upon reduction of Claspin or
Timeless levels in HCT116 cells (Supplementary Fig. 4d).
Together, these data indicate that high levels of Claspin and
Timeless in HC116 cells protect them from endogenous RS,
independently of their ability to activate CHK1.
Claspin and Timeless promote genome stability in S phase.
The budding yeast homologs of Claspin and Timeless,
namely Mrc1 and Tof1, promote replication fork progression
through sequences that are intrinsically difficult to replicate, in a
checkpoint-independent manner39,51,52. Common fragile sites
(CFSs) are regions of the human that are replicated in late S
phase and break more frequently under RS conditions53,54. To
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determine whether late-replicating regions are particularly diffi-
cult to replicate in the absence of Claspin and Timeless, sh-Ctrl,
sh-CLSPN, and sh-TIM HCT116 cells were sorted by flow cyto-
metry and were collected in G1, early S, and late S phase (Fig. 4e).
Immunoblotting of γ-H2AX in each subpopulation confirmed
that γ-H2AX levels were globally higher during S phase in sh-
CLSPN and sh-TIM cells compared to control cells and revealed
that γ-H2AX was preferentially enriched at late-replicating
regions in the absence of Timeless (Fig. 4f). We also monitored
replication fork progression in the same samples by DNA
combing. In sh-CLSPN cells, we observed an overall reduction of
fork speed relative to control cells, regardless of the S-phase stage
(Fig. 4g). In sh-TIM cells, this slowdown of the forks was only
detected in late S phase, which is consistent with their increased
level of γ-H2AX (Fig. 4f). Since CFSs replicate late during S
phase, we next asked whether these loci break more frequently in
the absence of Claspin and Timeless. To this end, we have ana-
lyzed copy-number variations (CNVs) and loss of heterozygosity
in these cells by single-nucleotide polymorphism comparative
genomic hybridization (SNP-CGH). This analysis revealed 33
recurrent rearrangements in sh-Ctrl cells (Supplementary Fig. 4e),
which are typical of HCT116 cells55. In addition, 14 specific
Claspin Claspin
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Fig. 2 Coordinated upregulation of Claspin, Timeless, and CHK1 protein levels in cancer cell lines. aWestern blot analysis of the levels of Claspin, Timeless,
CHK1, and ATR in human cancer cell lines (U2OS, HeLa, and HCT116) and in immortalized primary fibroblasts (IMR90). b Claspin, Timeless, CHK1, RAD17,
and ATR in colorectal cancer HCT116 cells, immortalized primary fibroblasts (BJ) and immortalized epithelial cells (RPE-1 and MCF10A). c Correlation
analysis of the abundance of DDR proteins in 50 colorectal cancer cell lines
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Fig. 3 The overexpression of Claspin and Timeless promotes cell growth in a checkpoint-independent manner. a Levels of Claspin, Timeless, and CHK1 in
immortalized IMR90 fibroblasts and in HCT116 cells transduced with a control shRNA (sh-Ctrl) or with shRNAs against Claspin (sh-CLSPN) and Timeless
(sh-TIM). b Growth of HCT116 transduced with doxycycline-inducible shRNAs against Claspin (sh*-CLSPN) or Timeless (sh*-TIM) or with a control
shRNA (sh*-Ctrl). Cell growth was determined 48 h after addition of doxycyclin. **p < 0.05. c Anchorage-independent growth assay. HCT116 cells
transduced with sh*-Ctrl, sh*-CLSPN and sh*-TIM inducible shRNAs were grown 2 weeks in soft agar medium (0.7%) in the absence (−Dox) or the
presence (+Dox) of Doxycyclin. Colonies were visualized by microscopy and mean colony size was determined with MetaMorph. Representative images
are shown. d Western blot analysis of CHK1 phosphorylation (p-CHK1 and S317) in asynchronous sh-Ctrl, sh-CLSPN, and sh-TIM HCT116 cells treated for
0, 1, or 6 h with 10 mM HU. e Checkpoint-dependent degradation of CDC25A in sh-Ctrl, sh-CLSPN, and sh-TIM HCT116 cells treated for 0 or 6 h with
10mM HU and 300 nM of the CHK1 inhibitor UCN01
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rearrangements were detected in sh-CLSPN cells and 22 in sh-
TIM cells, almost half of which colocalized with CFSs (Supple-
mentary Fig. 4e, f). Collectively, these data indicate that increased
levels of Claspin and Timeless promote replication fork pro-
gression and prevent genomic instability in regions of the genome
that are intrinsically difficult to replicate, such as CFSs.
Claspin and Timeless protect cells from oncogenic RS. Spon-
taneous DNA repair foci are frequently detected at early stages
of tumorigenesis as a consequence of oncogene-induced
RS3,7,12,13,56,57, but generally disappear at later stages, which
suggests that cancer cells adapt to RS. To determine whether the
overexpression of Claspin and Timeless helps cells tolerate
oncogene-induced RS, an oncogenic form of Ras (RasV12) was
expressed in immortalized BJ-hTERT fibroblasts with a
doxycyclin-inducible promoter. As expected, RasV12 increased the
levels of phospho-CHK1 and γH2AX (Supplementary Fig. 5a)
and induced replication fork progression defects (Supplementary
Fig. 5b) as reported by others12,13,58. We also observed an
induction of p16 expression (Supplementary Fig. 5c), indicating
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After 60 days of RasV12 expression, a population of cells escaping
senescence was detected which is consistent with earlier
studies59,60. These cells showed no detectable levels of p16
(Supplementary Fig. 5c), but were unable to form colonies, sug-
gesting that they were not tumorigenic.
Next, we isolated thirteen individual clones from the
population of OIS-resistant BJ-Rasv12 cells and the expression
of ATR, Claspin, Timeless, and CHK1 was analyzed by qRT-
PCR. Remarkably, the majority of these clones showed at least a
50% increase in the levels of Claspin and CHK1 mRNAs
compared to BJ-hTERT, whereas ATR levels remained
unchanged (Fig. 5a). Among them, the clones #4 and #5
overexpressing both Claspin and Timeless were selected for
further analyses, together with clone #8, in which these factors
were not overexpressed. Western blot analyses confirmed that
clones #4 and #5 (but not clone #8) contained increased protein
levels of Claspin, Timeless, and CHK1, whereas levels of ATR
and Rad17 did not vary between the three clones (Fig. 5b).
Interestingly, all three clones displayed increased levels of
phospho-CHK1 and γ-H2AX compared to BJ-hTERT cells,
indicating the persistence of an oncogene-induced RS (Fig. 5c).
Yet, these clones grew more rapidly than BJ-hTERT or BJ-RasV12
cells, suggesting that they have acquired the capacity to tolerate
chronic RS (Fig. 5d).
Since the primary manifestation of RS is a slowdown of
replication forks, we next monitored fork progression in clones #4,
#5, and #8 by DNA fiber spreading. Remarkably, the slow fork
progression induced by RasV12 was completely suppressed in
clone #4 and fork progression was even faster in clone #5 than in
unchallenged BJ-hTERT cells (Fig. 5e). These data suggested that
clones #4 and #5 have acquired new properties allowing them to
replicate efficiently in presence of RS. Interestingly, clone
#8 showed an impaired fork progression (Fig. 5e), suggesting that
these cells have adopted a different strategy than clones #4 and #5
to tolerate RS. To identify the pathway(s) potentially involved in
this adaptation process, we analyzed the transcriptome of clones
#4, #5, and #8 and compared it to BJ-hTERT and BJ-RasV12 cells.
Extensive analysis of differentially expressed genes with GO-
TERM, KEGG, and REACTOME failed to identify obvious
patterns that could explain their phenotypes. Since resistance to
RS depends on E2F transcription61, we have performed a
differential expression analysis was performed using a SAM
multiclass analysis focusing on different set of genes induced by
E2F or E2F hyperactivation (siE2F6), HU exposure62, and genes
involved in DNA repair (http://repairtoire.genesilico.pl). Among
these, only DNA repair genes allowed a good separation between
clone #4 and #5 and BJ or BJ-Ras cells, clone #8 showing
intermediate profiles (Supplementary Fig. 5d). These data suggest
that other overexpressed factors contribute to RS tolerance,
besides Claspin and Timeless.
Since clone #4 and #5 overexpress a large number of replication
factors besides Claspin and Timeless (Fig. 5f, Fold change > 1.5;
FDR= 0), we next asked whether depletion of only Claspin or
Timeless would be sufficient to prevent RS tolerance, as shown
above for HCT116 cells (Fig. 4d). To address this possibility,
clone #4 and #5 were transfected with siRNA pools against
Claspin and Timeless (Fig. 6a) and fork progression was
monitored by DNA fiber spreading. This analysis confirmed the
slow fork phenotype induced by the expression of RasV12 in BJ
cells and the ability of clones #4 and #5 (but not #8) to restore a
normal fork progression despite the induction of RasV12 (Fig. 6b).
Remarkably, this adaptation was lost upon depletion of Claspin or
Timeless in clones #4 and #5, as manifested by slower fork
progression (Fig. 6b) and increased γ-H2AX levels (Supplemen-
tary Fig. 6a). These data suggest that the overexpression of
Claspin and Timeless is a spontaneous event that is selected at
early stages of the cancer process to protect cells from chronic RS.
To determine whether the overexpression of Claspin or
Timeless is not only necessary but also sufficient to promote
resistance to oncogene-induced RS, these proteins were expressed
in BJ-Rasv12 (Supplementary Fig. 6b) and in U2OS-CycE cells
(Fig. 6c) and their ability to restore normal fork progression was
monitored by DNA fiber spreading after induction of RasV12 in
BJ-hTERT cells or CycE in U2OS cells. In BJ-Rasv12 cells, the
overexpression of Claspin, Timeless, or both proteins rescued fork
slowdown induced by RasV12 in BJ-hTERT cells (Supplementary
Fig. 6c) and by CycE in U2OS cells (Fig. 6d). Together, these data
indicate that increased levels of Claspin or Timeless is sufficient to
protect cells from oncogene-induced RS.
Discussion
Oncogene-induced RS plays an active role in tumorigenesis by
promoting genomic instability and by inducing a selective pres-
sure for the inactivation of DDR factors such as TP53 and ATM1.
Spontaneous DNA damage and genomic instability are caused by
DNA replication problems occurring in pretumoral lesions57.
However, DDR signals decrease during cancer development, as
illustrated in bladder cancer2. Recent evidence indicates that this
decreased DDR signaling correlates with increased expression of
the checkpoint mediator Timeless in bladder tumors25. However,
the mechanism by which Timeless promotes adaptation to
oncogene-induced RS is currently unclear.
Here, we have monitored the expression of Claspin and
Timeless in primary breast, colorectal, and lung cancers and
compared it to other components of the ATR-CHK1 pathway.
This analysis revealed that Claspin, Timeless, and CHK1 are
overexpressed in a coordinated manner in these three cancers
whereas the checkpoint sensors ATR, RAD17, and RAD9 are not.
We confirmed that Claspin and Timeless protein levels are much
Fig. 4 Reduction of Claspin and Timeless levels in HCT116 cells increases spontaneous replication stress and slows down fork progression.
a Immunofluorescence analysis of spontaneous γ-H2AX foci in EdU-positive sh-Ctrl, sh-CLSPN and sh-TIM HCT116 cells. Cells were pulse labeled for
10min with EdU prior to analysis. Representative images are shown. Scale bar, 5 µm. b Quantification of γ-H2AX signal intensity in EdU-positive sh-Ctrl,
sh-CLSPN, and sh-TIM cells. cWestern blot analysis of H2AX phosphorylation on Ser139 in untreated sh-Ctrl, sh-CLSPN, and sh-TIM HCT116 cells. d DNA
combing analysis of replication fork progression in sh-Ctrl, sh-CLSPN, and sh-TIM HCT116 cells. Asynchronous cultures were pulse labeled for 10 min with
IdU and 20min with CldU. DNA fibers were extracted, stretched on silanized coverslips and analyzed by immunofluorescence using antibodies against IdU,
CldU, and ssDNA. The length of CldU tracks was determined for three independent experiments. Median lengths are indicated in red. ****p < 0.0001,
***p < 0.001. Mann–Whitney rank sum test. e Exponentially growing sh-Ctrl, sh-CLSPN, and sh-TIM HCT116 cells were labeled for 10 min with IdU, 20min
with CldU and were sorted by FACS according to their DNA content. G1, early S phase (ES), and late S phase (LS) cells were collected for further analysis.
f Western blot analysis of γ-H2AX levels in sh-Ctrl, sh-CLSPN, and sh-TIM HCT116 cells collected in G1, early S phase (ES), and late S phase (LS). Relative
levels calculated for three independent experiments after normalization to tubulin are shown. g DNA combing analysis of replication fork speed in sh-Ctrl,
sh-CLSPN, and sh-TIM HCT116 cells collected in early S and late S. Median lengths of CldU tracks were determined for three independent experiments and
indicated in red. ****p < 0.0001, ***p < 0.001, ns nonsignificant. Mann–Whitney rank sum test
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higher in cancer cell lines relative to immortalized fibroblasts,
which is consistent with earlier studies63,64. Moreover, we
observed a tight correlation between the abundance of Claspin,
Timeless, and CHK1 proteins the proteomic landscape of 50
colon cancer cell lines43. Together, these data indicate that the
downstream components of the ATR-CHK1 pathway define a
functional module that is specifically enhanced in cancer cells.
Importantly, we also found that in low-grade NSCLC,
increased expression of Claspin, Timeless, and CHK1 (but not
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Fig. 5 Primary fibroblasts adapt to oncogene-induced replication stress by overexpressing Claspin and Timeless. a Immortalized BJ-hTERT cells expressing
an oncogenic version of Ras (Rasv12) under the control of a doxycyclin-inducible promoter were grown for 60 days in the presence of Dox to induce
oncogene-induced senescence (OIS). Thirteen individual clones escaping senescence were isolated. The expression of Claspin, Timeless, CHK1, and ATR
mRNAs was determined by qRT-PCR in these clones and in BJ-hTERT cells expressing or not RasV12 after normalization of mRNA levels to HPRT and 18S.
BJ-hTERT and BJ-RasV12 cells were grown in presence of doxycyclin 8 days before analysis. b Western blot analysis of Claspin, Timeless, CHK1, ATR,
RAD17 protein levels in BJ-hTERT, BJ-Rasv12 cells, and in clones #4, #5, and #8. cWestern blot analysis of phospho-CHK1 (S345) and γ-H2AX in BJ-hTERT
and BJ-Rasv12 cells and in clones #4, #5, and #8. d DNA fiber spreading analysis of fork progression in these cells after 10min IdU and 20min CldU pulses.
The median length of CldU tracks (red) was determined for five independent experiments. ****p < 0.0001, ***p < 0.001, ns nonsignificant difference with BJ
cells. Mann–Whitney rank sum test. e Growth of BJ-hTERT (black), BJ-Rasv12 (white) after 8 days in the presence of doxycyclin and clones #4, #5, and #8
(gray). f Hierarchical clustering analysis of BJ-hTERT, BJ-Rasv12, and clones #4, #5, and #8 based on the expression of DNA repair genes (in two
independent experiments: A and B). Blue: low expression, red: high expression
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the tumor. This finding is important because surgical resection is
the standard of care for NSCLC and recurrence after resection has
been reported in 30–75% of all cases from stage I to stage III65.
The current clinical staging based on anatomic or pathological
factors is insufficient to predict the evolution of the disease,
especially for early stage diseases. Our data indicate that Claspin
and Timeless could be used as prognostic markers to identify
patients who would benefit from adjuvant chemotherapy.
Claspin and Timeless have a dual role in checkpoint signaling
and in the maintenance of replication fork integrity34–36. To
determine which of these two activities promotes RS tolerance, we
have reduced the expression of Claspin and Timeless to levels that
impede cell growth without interfering with ATR-CHK1 signal-
ing. Conflicting results have been published regarding the impact
of Claspin and Timeless depletion on CHK1 activation10,66–69.
Our data indicate that residual levels of Claspin and Timeless are
sufficient to activate CHK1. Alternatively, other checkpoint
mediators such as TopBP1 and BRCA1 could be redundant with
Claspin and Timeless33,70. Our data indicate that the abundance
of TopBP1 and BRCA1 correlates with Claspin, Timeless, and
CHK1 in colon cancer cell lines, which would be consistent with
the latter hypothesis. In any case, we report here that the
reduction of Claspin and Timeless levels in cancer cell lines
reduced the speed of fork progression, increased the rate of fork
stalling and increased γ-H2AX levels in checkpoint-proficient
cells. We, therefore, propose that enhanced levels of Claspin and
Timeless protect cancer cells from endogenous RS in a
checkpoint-independent manner.
The mechanism by which an excess of Claspin and Timeless




























































































Fig. 6 Increased levels of Claspin and Timeless promote fork progression in cells expressing oncogenic Ras. a Protein levels of Claspin and Timeless in
clones #4 and #5 transfected with control (si-Ctrl), Claspin (si-CLSPN), and Timeless (si-TIM) siRNAs. b DNA fiber spreading analysis of fork progression
in clones #4 and #5 after depletion of Claspin and Timeless with siRNAs. Median CldU tracks length (red) were determined for three independent
experiments. ****p < 0.0001, ***p < 0.001, ns nonsignificant difference. Mann–Whitney rank sum test. c Levels of Claspin and Timeless in U2OS-CycE cells
transfected with GFP, Claspin, and Timeless plasmids. U2OS-CycE cells expressing Cyclin E under the control of a doxycyclin-inducible promoter were
grown during 6 days in the presence of Dox to induce replication stress. Then cells are transfected with plasmids to overexpress GFP, Claspin or Timeless
during 3 days before performing DNA spreading experiment. d DNA spreading analysis of experiment performed in c. DNA spreading was also performed
on U2OS-CycE cells growing without Dox. Median CldU tracks length (red) were determined for three independent experiments. ****p < 0.0001, ns
nonsignificant. Mann–Whitney rank sum test
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evidence indicates that these two proteins form a FPC together
with Tipin and interact with multiple components of the repli-
some to maintain the integrity of stressed forks32,34. This struc-
tural function of the FPC could help forks progress through
regions of the genome that are intrinsically difficult to replicate,
especially in the context of deregulated oncogenic pathways.
Interestingly, we have found that Timeless depletion affected
preferentially late-replicating regions of the genome, whereas
Claspin depletion impacted replication throughout S phase. These
data suggest that Claspin and Timeless have nonredundant
functions in the FPC, which is consistent with yeast data. Indeed,
the budding yeast orthologue of Timeless is required for stable
pausing at specific replication barriers, whereas the orthologue of
Claspin is not39,51. Moreover, Timeless facilitates fork progres-
sion through telomeric and pericentric chromatin71,72 and sti-
mulates the activity of the DDX1 helicase on structured DNA
substrates that could be more abundant in late-replicating,
repeated regions of the genome73. Interestingly, recent evidence
indicates that Timeless is displaced from the replisome under RS
conditions to slowdown fork progression and prevent deleterious
consequences for the integrity of the genome74. In this context,
enhanced levels of Claspin, Timeless, and Tipin in cancer cells
may promote the reassembly of the FPC and accelerate fork
restart. This is consistent with the fact that overexpressed Claspin
and Timeless accumulate on chromatin in HCT116 cells and
could be easily available to reform the FPC upon stress-induced
dissociation. Interestingly, the overexpression of Timeless in
bladder cancer is associated with increased genomic instability25.
It is, therefore, likely that the adaptation to oncogene-induced RS
mediated by enhanced Claspin and Timeless occurs at the
expense of genome integrity and would therefore promote cancer
progression.
Another important question raised by our study concerns the
mechanism by which cancer cells overexpress Claspin and
Timeless. The expression of Claspin and CHK1 depends on the
E2F pathway61,75, which are upregulated by oncogenes and
contributes to RS tolerance61. To determine whether the upre-
gulation of the E2F pathway is the initial event contributing to the
upregulation of Claspin and Timeless, we have overexpressed an
oncogenic form of Ras in immortalized primary fibroblasts and
monitored the expression of Claspin, Timeless in clones escaping
OIS12,13. Remarkably, a large fraction of these clones showed
increased levels of Claspin and to a lesser extent Timeless. We
also detected increased levels of CHK1 mRNAs, but not ATR,
which is consistent with the levels observed in tumor samples and
cancer cell lines. As in cancer cell lines, the depletion of Claspin
and Timeless in these clones increased oncogene-induced RS,
stressing the importance of these proteins the adaptation to stress.
Transcriptome analyses of these clones revealed complex and
heterogeneous gene-expression profiles that are not consistent
with a simple upregulation of the E2F pathway, but with a global
overexpression of a large group of DDR genes involved in fork
protection. Interestingly, one of the OIS-resistant clones did not
overexpress Claspin and Timeless, indicating that alternative
pathways exists to adapt to RS.
In conclusion, our work supports a model in which the over-
expression of Claspin and Timeless protects forks from chronic
RS by stabilizing the replisome without increasing the activation
of the ATR pathway. This would confer a proliferative advantage
to cancer cells experiencing chronic RS by promoting replication
fork progression without triggering an increased checkpoint
response, which would be detrimental to tumor growth. These
data indicate that Claspin and Timeless represent promising
targets for anticancer therapies targeting replication forks.
Moreover, they represent valuable prognostic markers for
patients with early NSCLC.
Methods
Tumor samples, RNA extraction, and statistical analysis. RNA samples were
extracted and quantified from 93 untreated primary lung adenocarcinomas, 206
primary breast cancers (PACS01 trial), and 74 primary colorectal carcinomas as
described27,41,42. Written informed consent was obtained from all patients before
testing and experiments conformed to the principles set out in the WMA
Declaration of Helsinki. DFS data were available for 72 low-stage (IA/IB/IIA/IIB)
lung cancer patients. All survival times were calculated from the date of surgery
and were estimated by the Kaplan–Meier method with 95% confidence intervals
(CI), using the following first-event definitions: loco-regional relapse, distant
metastasis, other cancer or death from any cause. Patients alive without disease are
censored at the date of last follow-up. Gene-expression values were divided into
two equal groups by taking the median value. Univariate analysis was performed
using the Log-rank test. Two-sided p values of less than 0.05 were considered
statistically significant. Statistical analyses were performed using STATA
12.0 software.
Immunohistochemistry. Paraffin-embedded specimens were obtained from 14
breast cancer patients for immunohistochemical analysis. The procedures of
immunostaining were carried out with standard protocols by the PETRA-AMMICa
Facility (Gustave Roussy Institute, France). Briefly, 3 μm paraffin tissue slides were
deparaffinized after antigen retrieval and quenching of endogenous biotin, sections
were incubated at room temperature for 60 min with a rabbit anti-Timeless anti-
body (1/100, ab109512, Abcam). Antibody binding was detected using the EnVi-
sion Flex Dako kit (Agilent) and counterstaining was performed with Mayer’s
Hemalun solution.
Cell lines, cell culture, and drugs. The human HCT116 colorectal carcinoma cell
line was provided by A. Coquelle (IRCM, Montpellier, France). Normal human
fibroblasts IMR90 and BJ-hTERT were a gift of J-M Lemaitre (IGF, Montpellier,
France). MCF7 breast cancer cells were provided M. Piechaczyk (IGMM, Mon-
tpellier, France). HeLa cervical cancer cells and U2OS cells were a gift of M.
Benkirane (IGH, France), All cell lines were grown in high glucose Dulbecco’s
modified Eagle’s medium with ultraglutamine, supplemented with 10% heat
inactivated fetal bovine serum (FBS) and 10% antibiotics (Lonza). Cell lines were
grown at 37 °C in a humidified atmosphere of 5% CO2 and were tested for absence
of mycoplasma contamination.
Correlation analysis of proteomics data. Colorectal cancer cell line proteomics
data were retrieved from ref. 43. Correlation heatmaps were generated with the
Morpheus clustering web tool (https://software.broadinstitute.org/morpheus/)
using Pearson’s correlation.
Cell line transduction and plasmid transfection. pBABE-Puro H-RasV12 (n°
12545 Addgene) or Cyclin E and corresponding empty vectors were used to infect
either BJ hTERT cells or U2OS, respectively. Lentiviruses were produced by the
vectorology facility (BioCampus Montpellier) according to standard protocols76.
Plasmid transfection in BJ-Rasv12 cells was performed using Viromer Yellow
(Lipocalix) according to the manufacturer’s instructions. U2OS-CycE transfections
were performed using Interferin (Polyplus-transfection, Illkirch, France) according
to the manufacturer’s instructions. As a control, pMax-GFP plasmid (Lonza) was
used and to overexpressed Claspin and Timeless pcDNA3.1-Flag-claspin (Addgene
no. 12659) and pcDNA 4-Flag-Timeless (Addgene no. 22887) plasmids were used.
RNA interference and transfection. MISSION® TRC shRNA plasmid targeting
Claspin (TRCN0000130853) and Timeless (TRCN0000157801) and MISSION®
pLKO.1-puro Non-Mammalian shRNA Control Plasmid (shc002) (Sigma-Aldrich)
were used to produce lentiviruses expressing constitutive shRNA. TRIPZ inducible
lentiviral shRNA plasmid (Thermo Scientific Open Biosystems) targeting Claspin
(V2THS_200492) and Timeless (V2THS_47526) were used to produce lentiviruses
expressing inducible shRNAs on the vectorology facility (BioCampus Montpellier)76.
HCT116 cells were transduced with these different lentiviruses expressing individual
shRNA and heterogeneously-infected population of cells expressing shRNA was
selected with 1 μg/ml Puromycin. Inducible shRNA are expressed by addition of 2
μg/ml Doxycycline for three days before experiments. Infected cell populations were
maintained in culture for no more than one month. For siRNA transfection, On-
Target plus SMART pool (Dharmacon) against Claspin (L-005288-00) or against
Timeless (L-019488-00) were used. Hiperfect reagent (Qiagen) has been used for
HCT116 cells transfection and Amaxa cell line Nucleofector Kit R technology
(Lonza) for clones 4 and 5 transfection.
Immunoblotting. Cells were lysed in 2× Laemmli buffer at the concentration of
1 × 104 cells/µl. Lysates were treated with 3 μl of Benzonase (25 U/µl, Sigma) for 30
min at 37 °C. RPE-1 and MCF10A cells extracts were a gift of M. Mechali and R.
Fernandez de Luco labs respectively (IGH, France). Proteins were separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis, transferred to nitro-
cellulose membrane and analyzed by western immunoblotting with appropriate
antibodies: anti-Claspin (1/50, gift of T. Halazonetis, Geneva), anti-Timeless
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(1/1000, Interchim), anti-Actin (1/500, Sigma), anti-phospho Ser317-CHK1 or
Ser345-CHK1 (1/1000, Cell Signaling Technology, ref 2344S and 2348), anti-CHK1
(1/1000, Cell Signaling Technology, ref 2360), anti-Cdc25A (1/200, Santa Cruz, ref
sc-7389), anti-γ-H2AX (1/1000, Millipore, ref 05–636), anti-Tubulin (1/3000,
Abcam, ref ab-6161), anti-RPA (1/300, Abcam ref ab-79398), anti-ATR (1/1000,
Abcam, ref ab-10312), anti-RAD17 (1/1000, MBL, ref K0120-03), anti H3 (1/3000,
Abcam, ref ab-7191), anti-ras (1/500, BD, ref 610002), anti-Actin (1/500, Sigma ref
A4700). Blots were incubated with horseradish peroxidase-linked secondary anti-
body (GE Healthcare) and visualized using the ECL+ chemiluminescence method
(Pierce).
Cell fractionation. Cells were lysed with 0.2% Triton X-100 CSK buffer (10 mM
PIPES [pH 6.8], 100 mM NaCl, 300 mM sucrose, MgCl2, 1 mM EGTA, 1 mM
EDTA, proteases inhibitors cocktail (Complete, EDTA-free tablets; Roche), and
0.2% Triton X-100) for 10 min on ice. After centrifugation (0.8 × g for 5 min), the
supernatant is the soluble fraction (sup). The pellet was washed once more with
the same buffer and incubated 10 min on ice. After centrifugation (0.8 × g for
5 min) the pellet (chromatin fraction) was resuspended in 2× Laemmli buffer.
Cell proliferation quantification. The Cell Proliferation Reagent WST-1 (Sigma)
is used for the spectrophotometric quantification of cell proliferation.
Soft agar assay. Totally, 5 × 104 cells were resuspended in 3 ml of prewarmed
DMEM-10% FBS and were mixed with 3 ml of 0.8% agar solution (Sigma A5431)
in 10% DMEM and 1% FBS. A total of 1.5 ml of cell suspension is poured in three
wells containing a 2 ml prewarmed layer of 1% Agar in 10% DMEM and 1% FBS.
Totally, 1 ml of medium is added on the upper agarose layer and plates are
incubated for 15 days at 37 °C. Top medium is replaced every three days. Colonies
were visualized with a microscope and colony sizes were determined with the
MetaMorph software.
Colony formation assay. HCT116 cells are plated in 6-well plates at 20% con-
fluence and are grown for 2 weeks. Cells are washed twice with ice-cold phosphate-
buffered saline (PBS) and fixed for 10 min with ice-cold methanol. Colonies are
stained for 10 min at room temperature with 0.5% crystal violet in 25% methanol
and rinsed with ddH20.
Cell sorting. After trypsinization, asynchronous cells were resuspended in PBS-
3mM EDTA (107 cells/500 μL cells) and fixed in ETOH 70% as in the previous
section. After two washes in ice-cold PBS, cells were resuspended at the con-
centration of 5 × 106 cells/ml in staining buffer (3 mM EDTA, 0.05% NP40, 50 µg/
ml propidium iodide, 1 mg/ml RNase A in PBS). Cells in G1, early S, and late S
phase were collected according to their DNA content with a FACS-Aria cell sorter
(Becton Dickinson) at the IGMM-MRI facility (Montpellier, France). Immediately
after collection, each fraction of cells was divided in two parts: one for proteins
analysis by western blot and one for DNA combing.
Flow cytometry analysis of γ-H2AX and EdU. Asynchronous cells were pulse
labeled with 10 μM EdU (5-ethynyl-2′-deoxyuridine) for 30 min before harvesting.
Cells were trypsinized as usual, washed once with cold PBS and once with
PBS–bovine serum albumin (BSA) 1%. A total of 1 × 106 cells were fixed in 2%
formaldehyde–PBS for 10 min in the dark at room temperature and washed twice
in 1 ml of cold PBS/1% BSA. cells were permeabilized by addition of 200 μL of
saponin buffer (0.1% saponin in PBS/0.5% BSA) for 10 min at 4 °C and incubated
with γ-H2AX antibody (Millipore 05-636) diluted at 1/500 in 100 μL of saponin
buffer for 2 h at room temperature in the dark. After two washes in saponin buffer
cells were incubated in 50 μL of saponin buffer containing the secondary anti-
mouse Alexa 488 antibody (Molecular probes: A-11001) at 1/500 for 30 min at
room temperature in the dark. Cell were washed twice in 0.5 ml of saponin buffer
and resuspended in 100 μL of Click-it reaction mix (86.5 µl H2O, 3 µl CuSO4
(0.1 M), 0.5 µl Alexa fluor 647-azide (Thermo Fisher Scientific), 10 µl of 100 mM
freshly prepared vitamin C) for 30 min at room temperature in the dark. Cells were
washed twice with 0.5 ml PBS/1% BSA and resuspended in 0.5 ml 1% BSA/PBS
containing 0.1 mg/ml RNase A and 2 µg/ml DAPI. After 30 min at 37 °C samples
were analyzed with the Miltenyi Macs Quant analyzer and FlowJo software at the
IGH-MRI facility (Montpellier, France).
Single-nucleotide polymorphism comparative genomic hybridization. CNVs in
sh-Ctrl, sh-CLSP, and sh-TIM cells were determined using Illumina Infinium
technology, using BeadChips (HumanHap300 duo) containing 317000 SNP tags.
The cnvPartition plug-in of the Illumina BeadStudio software was used to annotate
CNVs and estimate copy number.
DNA combing and DNA fiber spreading. DNA combing and DNA fiber
spreading were performed as described48,49,77 using the following combination of
antibodies. Primary antibody mix: Mouse anti-BrdU to detect IdU (1/100 PBS/T,
BD 347580), Rat anti-BrdU to detect CldU (1/100 PBS/T, Eurobio clone BU1/75),
Anti-ssDNA (1/100 PBS/T, auto anti-ssDNA, DSHB). Secondary antibody mix:
Goat anti-rat Alexa 488 (1/100 PBS/T, Molecular Probes, A11006); Goat anti-
mouse IgG1Alexa 546 (1/100 PBS/T, Molecular Probes, A21123); Goat anti-Mouse
IgG2a Alexa 647 (1/50 PBS/T, Molecular Probes, A21241). Statistical analysis of
track lengths is performed with GraphPad Prism 7.0.
Immunofluorescence. HCT116 cells were seeded on cover glasses and labeled with
10 mM EdU for 15 min. Cells were then fixed with 2% paraformaldehyde and
permeabilized using 0.1% Triton X-100. Immunodetection of γH2AX in S-phase
was performed overnight at 4 °C using a specific antibody (1/100; 05-636, Milli-
pore). Click-it chemistry was performed according to instructions. Images were
acquired using an LSM780 Zeiss confocal microscope. Mean fluorescence intensity
of γ-H2AX in EdU-positive cells was quantified with CellProfiler.
Transcriptome analysis. RNA sequencing (RNA-seq) libraries were prepared
using the Illumina TruSeq Stranded mRNA Library Prep Kit. Paired-end RNA-seq
were performed with an Illumina NextSeq sequencing instrument (Helixio,
France). RNA-seq read pairs were mapped to the reference human GRCh37
genome using the STAR aligner78. Statistical analyses were performed with R
(v3.2.3) and R packages developed by BioConductor project. The expression level
of each gene was summarized and normalized using DESeq2 R/Bioconductor
package79. Differential expression analysis was performed using SAM multiclass
analysis (samr package). Genes with a fold change > 1.5 and a FDR < 0.05 were
considered as significantly differentially expressed.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The datasets generated during and/or analyzed during the current study are available
from the corresponding author on reasonable request. The RNA-seq datasets generated
and analyzed during the current study (Fig. 5f and Supplementary Fig. 5d) are available
in the GEO repository, accession number: GSE123380. A reporting summary for this
Article is available as a Supplementary Information file.
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